Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Capillary Malformation Treatment & Management

  • Author: Richard J Antaya, MD; Chief Editor: Dirk M Elston, MD  more...
 
Updated: Aug 20, 2014
 

Medical Care

Affected areas can be tattooed with a skin-colored pigment; however, this is not routinely performed.

Use of a cosmetic cover-up is an alternative. Opaque makeup, sold commercially without a prescription under brand names like Dermablend and Covermark, disguises capillary malformations but does not treat them.

At least one report describes partial clearing of a capillary malformation on the arm of a 59-year-old woman after the use of topical imiquimod under plastic wrap occlusion 5 times per week for 4 weeks. The authors attribute the response to antiangiogenic properties of imiquimod through the induction of tissue inhibitor of matrix metalloproteinase-1, an inhibitor of vascular tumor growth.[30] A prospective, controlled trial demonstrated that imiquimod application 3 times weekly for 8 weeks after pulsed-dye laser (PDL) therapy resulted in measurable objective improvement in lightening of the stain than PDL therapy followed by placebo.[31]

Next

Surgical Care

Flashlamp-pumped pulsed-dye laser (PDL) surgery is the treatment of choice for capillary malformations.[32, 33, 34] It uses selective photothermolysis with ultrashort pulses of monochromatic yellow light (585-600 nm), which are preferentially absorbed by oxyhemoglobin in the abnormally dilated superficial dermal blood vessels. Flashlamp-pumped PDL causes selective destruction of these superficial target blood vessels, inducing intravascular coagulation and rupture of some smaller vessels, which later become absorbed and replaced by collagen. The ultrashort laser pulses are shorter than the thermal relaxation time of the vessels, thereby limiting adjacent dermal and epidermal heating and preventing subsequent damage. Kono et al published a thorough review of PDL therapy for capillary malformations,[35] which examines many of the idiosyncrasies of this treatment modality.

Despite few, high quality, randomized-controlled trials comparing the efficacy amongst various laser or light sources, PDL has proven to be effective for clinically relevant clearance of capillary malformations. A Cochrane review demonstrated overall greater than 25% reduction in redness after 1-3 treatments in over half of all subjects treated in these studies.[32]

Skin treated with a PDL immediately develops edema and purpura, the latter of which generally last 1-2 weeks. Flashlamp-pumped PDL is relatively safe; major risks include pigmentation alterations (hyperpigmentation, which is always transient, and potentially permanent hypopigmentation), crusting, and, rarely, scarring. Immediate adverse events associated with PDL therapy are pain (a hot snapping sensation that can increase with repeated pulses) and combustion (especially of hair-bearing areas and in the presence of increased ambient oxygen). PDL therapy can be performed on patients with skin types V and VI, but with a potentially higher risk of pigmentary complications.

Some authorities advocate treatment beginning as early as 7-14 days of life, yet the age at which laser treatment achieves maximal response is unknown. Some studies indicate a better response if treatment is commenced before the patient is aged 1 year, while others reveal no difference. From a psychosocial perspective, treatment commencing in infancy is most beneficial.

The response rate depends on several variables. The first is anatomical location, with rates in descending order of location from best to worst as follows: neck, torso, face, and hand and arm; and with rates in descending order of location from best to worst for facial capillary malformations as follows: forehead, lateral part of the face, temple, and central part of the face. The second variable is size; smaller lesions appear to have higher response rates. These variables are influenced by the histologic features of capillary malformations. In 2004, videodermoscopy was used to demonstrate that capillary malformations with smaller vessels deep in the dermis were the most difficult to eradicate with PDL.[36]

Investigations are ongoing to explore methods to improve the outcome of laser surgery, including adjunctive use of exogenous heat,[37] the topical application of the angiogenesis inhibitors rapamycin[38] or imiquimod[39] postoperatively, or intravenous porphyrin derivatives (photodynamic therapy)[40] prior to laser surgery. While the early observations are promising, these interventions are strictly experimental at this time.

See the images below.

Capillary malformation on the left preauricular as Capillary malformation on the left preauricular aspect of the cheek, the ear, and the neck in a neonate (same patient as in Media Files 3-4).
Same patient as in Media Files 2 and 4 immediately Same patient as in Media Files 2 and 4 immediately after test spots with the pulsed-dye laser at 585 nm. Note the purpuric macules where the laser impacted in a linear distribution on the preauricular aspect of the cheek.
Same patient as in Media Files 2-3 after 4 treatme Same patient as in Media Files 2-3 after 4 treatments with the pulsed-dye laser. Treatments were given at 2-month intervals in an outpatient setting using topical anesthetic.

Redarkening of capillary malformations can occur in patients treated by laser.[41] The exact percentage of patients in which this occurs is unknown, with estimates from 11-50%. Currently, no characteristics help predict which lesions will redarken. No capillary malformations darken to the degree they were prior to embarking on laser treatment. Fifty-nine percent of patients are satisfied with the overall treatment result.[42]

Earlier laser therapies that caused an unacceptably high rate of scarring are not recommended; these therapies include carbon dioxide laser, copper vapor laser, and argon laser. Other modalities, such as intense pulsed light devices,[43] alexandrite laser,[44] and the long-pulse[45] or frequency-doubled Nd:YAG laser,[46] are reported to be effective in certain instances, but they are generally considered to have higher complication rates than the PDL.

Previous nonlaser treatments determined unreliable or deleterious include surgical excision, radium implants, cryosurgery, electrocautery, sclerotherapy, and grenz ray radiotherapy.

Innovative methods such as laser speckle imaging[47] and photoacoustic imaging[48] to more accurately assess the vessel density, depth, and diameter and immediate efficacy of laser surgery are ongoing and represent the next frontiers toward improved treatment outcomes.

Previous
Next

Consultations

Consult a pediatric dermatologist, a general dermatologist, or a specialist at a laser center or a vascular lesion center for evaluation and early intervention if indicated.

Consult an ophthalmologist for tonometry to exclude glaucoma in infants with CN V1 and CN V2 or eyelid involvement. An ophthalmologist can also evaluate for evidence of ocular capillary malformation in patients with Sturge-Weber syndrome.

Consult a radiologist or refer the patient to a vascular lesion center if underlying complicating vascular, neural, or skeletal malformations are suspected. If a leg-length discrepancy is apparent in a patient with a lower extremity capillary malformation, consult a pediatric orthopedic surgeon.

Consult a neurologist if Sturge-Weber syndrome is suspected.

Previous
 
 
Contributor Information and Disclosures
Author

Richard J Antaya, MD Director of Pediatric Dermatology, Professor, Departments of Dermatology and Pediatrics, Yale University School of Medicine

Richard J Antaya, MD is a member of the following medical societies: American Academy of Dermatology, Society for Pediatric Dermatology, American Academy of Pediatrics

Disclosure: Nothing to disclose.

Specialty Editor Board

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Texas Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

Van Perry, MD Assistant Professor, Department of Medicine, Division of Dermatology, University of Texas School of Medicine at San Antonio

Van Perry, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Mark W Cobb, MD Consulting Staff, WNC Dermatological Associates

Mark W Cobb, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Society of Dermatopathology

Disclosure: Nothing to disclose.

References
  1. Happle R. What is a capillary malformation?. J Am Acad Dermatol. 2008 Dec. 59(6):1077-9. [Medline].

  2. Smoller BR, Rosen S. Port-wine stains. A disease of altered neural modulation of blood vessels?. Arch Dermatol. 1986 Feb. 122(2):177-9. [Medline].

  3. Chang CJ, Yu JS, Nelson JS. Confocal microscopy study of neurovascular distribution in facial port wine stains (capillary malformation). J Formos Med Assoc. 2008 Jul. 107(7):559-66. [Medline].

  4. Vural E, Ramakrishnan J, Cetin N, Buckmiller L, Suen JY, Fan CY. The expression of vascular endothelial growth factor and its receptors in port-wine stains. Otolaryngol Head Neck Surg. 2008 Oct. 139(4):560-4. [Medline].

  5. Kaji N, Nagase T, Nagase M, Koshima I. Changes in angiogenic gene expression in a case of expanded capillary malformation: does an expanded capillary malformation grow?. Ann Plast Surg. 2005 Jun. 54(6):645-50. [Medline].

  6. Shirley MD, Tang H, Gallione CJ, Baugher JD, Frelin LP, Cohen B. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med. 2013 May 23. 368(21):1971-9. [Medline].

  7. Boon LM, Mulliken JB, Vikkula M. RASA1: variable phenotype with capillary and arteriovenous malformations. Curr Opin Genet Dev. 2005 Jun. 15(3):265-9. [Medline].

  8. Hershkovitz D, Bergman R, Sprecher E. A novel mutation in RASA1 causes capillary malformation and limb enlargement. Arch Dermatol Res. 2008 Aug. 300(7):385-8. [Medline].

  9. Hershkovitz D, Bercovich D, Sprecher E, Lapidot M. RASA1 mutations may cause hereditary capillary malformations without arteriovenous malformations. Br J Dermatol. 2008 May. 158(5):1035-40. [Medline].

  10. Motley RJ, Lanigan SW, Katugampola GA. Videomicroscopy predicts outcome in treatment of port-wine stains. Arch Dermatol. 1997 Jul. 133(7):921-2. [Medline].

  11. Lanigan SW, Cotterill JA. Psychological disabilities amongst patients with port wine stains. Br J Dermatol. 1989 Aug. 121(2):209-15. [Medline].

  12. Sheehan DJ, Lesher JL Jr. Pyogenic granuloma arising within a port-wine stain. Cutis. 2004 Mar. 73(3):175-80. [Medline].

  13. da Silva AD, Silva CA, de Camargo Moraes P, Thomaz LA, Furuse C, de Araújo VC. Recurrent oral pyogenic granuloma in port-wine stain. J Craniofac Surg. 2011 Nov. 22(6):2356-8. [Medline].

  14. Pratt AG. Birthmarks in infants. AMA Arch Derm Syphilol. 1953 Mar. 67(3):302-5. [Medline].

  15. Afsar FS, Ortac R. Acquired port-wine stain in a pediatric patient. J Cutan Med Surg. 2006 May-Jun. 10(3):151-3. [Medline].

  16. Geronemus RG, Ashinoff R. The medical necessity of evaluation and treatment of port-wine stains. J Dermatol Surg Oncol. 1991 Jan. 17(1):76-9. [Medline].

  17. Maari C, Frieden IJ. Klippel-Trénaunay syndrome: the importance of "geographic stains" in identifying lymphatic disease and risk of complications. J Am Acad Dermatol. 2004 Sep. 51(3):391-8. [Medline].

  18. Ch'ng S, Tan ST. Facial port-wine stains - clinical stratification and risks of neuro-ocular involvement. J Plast Reconstr Aesthet Surg. 2008 Aug. 61(8):889-93. [Medline].

  19. Pascual-Castroviejo I, Pascual-Pascual SI, Velazquez-Fragua R, Viano J. Sturge-Weber syndrome: study of 55 patients. Can J Neurol Sci. 2008 Jul. 35(3):301-7. [Medline].

  20. Huiras EE, Barnes CJ, Eichenfield LF, Pelech AN, Drolet BA. Pulmonary thromboembolism associated with Klippel-Trenaunay syndrome. Pediatrics. 2005 Oct. 116(4):e596-600. [Medline].

  21. Samimi M, Maruani A, Bertrand P, Arbeille P, Lorette G. Arterial blood flow in limbs with port-wine stains can predict length discrepancy. Br J Dermatol. 2009 Jan. 160(1):219-20. [Medline].

  22. Lee MS, Liang MG, Mulliken JB. Diffuse capillary malformation with overgrowth: a clinical subtype of vascular anomalies with hypertrophy. J Am Acad Dermatol. 2013 Oct. 69(4):589-94. [Medline].

  23. Toriello HV, Mulliken JB. Accurately renaming macrocephaly-cutis marmorata telangiectatica congenita (M-CMTC) as macrocephaly-capillary malformation (M-CM). Am J Med Genet A. 2007 Dec 15. 143A(24):3009. [Medline].

  24. Kuint J, Globus O, Ben Simon GJ, Greenberger S. Macrocephaly-capillary malformation presenting with fetal arrhythmia. Pediatr Dermatol. 2012 May-Jun. 29(3):384-6. [Medline].

  25. Guggisberg D, Hadj-Rabia S, Viney C, et al. Skin markers of occult spinal dysraphism in children: a review of 54 cases. Arch Dermatol. 2004 Sep. 140(9):1109-15. [Medline].

  26. Tubbs RS, Wellons JC 3rd, Iskandar BJ, Oakes WJ. Isolated flat capillary midline lumbosacral hemangiomas as indicators of occult spinal dysraphism. J Neurosurg. 2004 Feb. 100(2 Suppl Pediatrics):86-9. [Medline].

  27. Happle R. Phacomatosis pigmentovascularis revisited and reclassified. Arch Dermatol. 2005 Mar. 141(3):385-8. [Medline].

  28. Lapidoth M, Ben Amitai D, Feinmesser M, Akerman L. Capillary malformation associated with angiolipoma: analysis of 127 consecutive clinic patients. Am J Clin Dermatol. 2008. 9(6):389-92. [Medline].

  29. Happle R. Loss of heterozygosity in human skin. J Am Acad Dermatol. 1999 Aug. 41(2 Pt 1):143-64. [Medline].

  30. Kouba DJ, Yip D, Fincher EF, Moy RL. Topical imiquimod in the treatment of a long-standing capillary malformation. Br J Dermatol. 2007 Nov. 157(5):1071-2. [Medline].

  31. Tremaine AM, Armstrong J, Huang YC, Elkeeb L, Ortiz A, Harris R, et al. Enhanced port-wine stain lightening achieved with combined treatment of selective photothermolysis and imiquimod. J Am Acad Dermatol. 2012 Apr. 66(4):634-41. [Medline]. [Full Text].

  32. Faurschou A, Olesen AB, Leonardi-Bee J, Haedersdal M. Lasers or light sources for treating port-wine stains. Cochrane Database Syst Rev. 2011 Nov 9. 11:CD007152. [Medline].

  33. Goldman MP, Fitzpatrick RE. Laser treatment of cutaneous vascular lesions. Goldman MP, Fitzpatrick RE, eds. Cutaneous Laser Surgery: The Art and Science of Selective Photothermolysis. 2nd ed. Mosby-Year Book: St. Louis, Mo; 1999. 37-74.

  34. Sivarajan V, Maclaren WM, Mackay IR. The effect of varying pulse duration, wavelength, spot size, and fluence on the response of previously treated capillary vascular malformations to pulsed-dye laser treatment. Ann Plast Surg. 2006 Jul. 57(1):25-32. [Medline].

  35. Kono T, Groff WF, Sakurai H. Treatment of port wine stains with the pulse dye laser. Ann Plast Surg. 2006 Apr. 56(4):460-3. [Medline].

  36. Sivarajan V, MacKay IR. The relationship between location, color, and vessel structure within capillary vascular malformations. Ann Plast Surg. 2004 Oct. 53(4):378-81. [Medline].

  37. Jia W, Aguilar G, Verkruysse W, Franco W, Nelson JS. Improvement of port wine stain laser therapy by skin preheating prior to cryogen spray cooling: a numerical simulation. Lasers Surg Med. 2006 Feb. 38(2):155-62. [Medline].

  38. Phung TL, Oble DA, Jia W, Benjamin LE, Mihm MC Jr, Nelson JS. Can the wound healing response of human skin be modulated after laser treatment and the effects of exposure extended? Implications on the combined use of the pulsed dye laser and a topical angiogenesis inhibitor for treatment of port wine stain birthmarks. Lasers Surg Med. 2008 Jan. 40(1):1-5. [Medline].

  39. Chang CJ, Hsiao YC, Mihm MC Jr, Nelson JS. Pilot study examining the combined use of pulsed dye laser and topical Imiquimod versus laser alone for treatment of port wine stain birthmarks. Lasers Surg Med. 2008 Nov. 40(9):605-10. [Medline]. [Full Text].

  40. Gu Y, Huang NY, Liang J, Pan YM, Liu FG. [Clinical study of 1949 cases of port wine stains treated with vascular photodynamic therapy (Gu's PDT)]. Ann Dermatol Venereol. 2007 Mar. 134(3 Pt 1):241-4. [Medline].

  41. Huikeshoven M, Koster PH, de Borgie CA, Beek JF, van Gemert MJ, van der Horst CM. Redarkening of port-wine stains 10 years after pulsed-dye-laser treatment. N Engl J Med. 2007 Mar 22. 356(12):1235-40. [Medline].

  42. Huikeshoven M, Koster PH, de Borgie CA, Beek JF, van Gemert MJ, van der Horst CM. Redarkening of port-wine stains 10 years after pulsed-dye-laser treatment. N Engl J Med. 2007 Mar 22. 356(12):1235-40. [Medline].

  43. Ozdemir M, Engin B, Mevlitoglu I. Treatment of facial port-wine stains with intense pulsed light: a prospective study. J Cosmet Dermatol. 2008 Jun. 7(2):127-31. [Medline].

  44. Tierney EP, Hanke CW. Alexandrite laser for the treatment of port wine stains refractory to pulsed dye laser. Dermatol Surg. 2011 Sep. 37(9):1268-78. [Medline].

  45. Yang MU, Yaroslavsky AN, Farinelli WA, et al. Long-pulsed neodymium:yttrium-aluminum-garnet laser treatment for port-wine stains. J Am Acad Dermatol. 2005 Mar. 52(3 Pt 1):480-90. [Medline].

  46. Pence B, Aybey B, Ergenekon G. Outcomes of 532 nm frequency-doubled Nd:YAG laser use in the treatment of port-wine stains. Dermatol Surg. 2005 May. 31(5):509-17. [Medline].

  47. Huang YC, Ringold TL, Nelson JS, Choi B. Noninvasive blood flow imaging for real-time feedback during laser therapy of port wine stain birthmarks. Lasers Surg Med. 2008 Mar. 40(3):167-73. [Medline]. [Full Text].

  48. Kolkman RG, Mulder MJ, Glade CP, Steenbergen W, van Leeuwen TG. Photoacoustic imaging of port-wine stains. Lasers Surg Med. 2008 Mar. 40(3):178-82. [Medline].

  49. Fonder MA, Mamelak AJ, Kazin RA, Cohen BA. Port-wine-stain-associated dermatitis: implications for cutaneous vascular laser therapy. Pediatr Dermatol. 2007 Jul-Aug. 24(4):376-9. [Medline].

  50. Garzon MC, Huang JT, Enjolras O, Frieden IJ. Vascular malformations: Part I. J Am Acad Dermatol. 2007 Mar. 56(3):353-70; quiz 371-4. [Medline].

  51. Mazereeuw-Hautier J, Syed S, Harper JI. Bilateral facial capillary malformation associated with eye and brain abnormalities. Arch Dermatol. 2006 Aug. 142(8):994-8. [Medline].

  52. Waner M, Suen JY. The treatment of vascular malformations. Hemangiomas and Vascular Malformations of the Head and Neck. New York, NY: John Wiley & Sons; 1999. 353-66.

  53. Waner M, Suen JY. The natural history of vascular malformations. Hemangiomas and Vascular Malformations of the Head and Neck. New York, NY: John Wiley & Sons; 1999. 52-62.

 
Previous
Next
 
Histopathologic features of a capillary malformation (nevus flammeus) showing telangiectatic vessels lined by mature-appearing endothelial cells.
Capillary malformation on the left preauricular aspect of the cheek, the ear, and the neck in a neonate (same patient as in Media Files 3-4).
Same patient as in Media Files 2 and 4 immediately after test spots with the pulsed-dye laser at 585 nm. Note the purpuric macules where the laser impacted in a linear distribution on the preauricular aspect of the cheek.
Same patient as in Media Files 2-3 after 4 treatments with the pulsed-dye laser. Treatments were given at 2-month intervals in an outpatient setting using topical anesthetic.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.